Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
19 oct. 2022 16h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on October 18, 2022, the Compensation Committee of Esperion’s Board of Directors granted 5 new...
Esperion to Participate in Upcoming September Investor Conferences
30 août 2022 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at Morgan Stanley’s 20th Annual Global Healthcare...
Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway
26 août 2022 08h16 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that bempedoic acid (NEXLETOL®) is now recommended as an important oral non-statin therapy for...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04 août 2022 16h05 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 2, 2022, the Compensation Committee of Esperion’s Board of Directors granted 13 new...
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
02 août 2022 07h00 HE
|
Esperion Therapeutics, Inc.
– Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023 – – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and...
Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
25 juil. 2022 15h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the establishment of its Scientific Advisory Board (SAB). The inaugural members of the Esperion SAB...
Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
03 juin 2022 12h30 HE
|
Esperion Therapeutics, Inc.
– Less than 1 in 10 were on any non-statin lipid lowering therapy – – Findings were shared at the National Lipid Association Scientific Sessions – ANN ARBOR, Mich., June 03, 2022 (GLOBE...
Esperion to Participate in the 2022 Jefferies Global Healthcare Conference
02 juin 2022 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming 2022 Jefferies...
Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors
01 juin 2022 16h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 01, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperion’s Board of Directors. Mr. Carroll will...
Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions
31 mai 2022 08h00 HE
|
Esperion Therapeutics, Inc.
– Highlight of accepted abstracts includes new real-world data on lipid-lowering therapy usage, submitted in partnership with UT Southwestern – – Accepted abstracts showcase breadth of Esperion’s...